Exhibit 99.1

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share data)

	March 31,
	2010			2009
ASSETS
Current assets:
Cash and cash equivalents	$	4,788		$	1,785
Short-term marketable securities		53,477			55,394
Accounts receivable, net		13,516			15,724
Inventories		9,211			14,777
Prepaid expenses and other current assets		1,676			809
Total current assets		82,668			88,489
Property and equipment, net		6,753			7,792
Intangible assets, net		2,979			4,359
Goodwill		37,170			31,295
Long-term marketable securities		—			3,721
Other assets		—			302
Total assets	$	129,570		$	135,958
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,764		$	5,550
Accrued expenses		13,011			10,818
Deferred revenue		1,289			1,211
Total current liabilities		18,064			17,579
Long-term deferred tax liability		3,040			2,086
Other long-term liabilities		510			310
Total liabilities		21,614			19,975
Commitments and contingencies
Stockholders’ equity:
Class B Preferred Stock, $.01 par value		—			—
Authorized - 1,000,000 shares; Issued and outstanding—none
Common stock, $.01 par value		375			367
Authorized - 100,000,000 shares; Issued - 37,484,018 shares at March 31, 2010 and 36,736,843 shares at March 31, 2009; Outstanding - 37,433,064 shares at March 31, 2010 and 36,685,889 shares at March 31, 2009
Additional paid-in-capital		372,425			362,097
Accumulated deficit		(263,015	)		(243,991	)
Treasury stock at cost - 50,954 at March 31, 2010 and March 31, 2009		(827	)		(827	)
Accumulated other comprehensive loss		(1,002	)		(1,663	)
Total stockholders’ equity		107,956			115,983
Total liabilities and stockholders’ equity	$	129,570		$	135,958

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except share data)

	Three Months Ended March  31,						Twelve Months Ended March  31,
	2010			2009			2010			2009
Revenue:
Products	$	22,828		$	19,384		$	84,765		$	72,512
Funded research and development		151			199			948			698
Total Revenue		22,979			19,583			85,713			73,210
Costs and expenses:
Cost of product revenue		6,239			5,498			22,529			20,437
Research and development		6,788			7,131			25,954			25,328
Selling, general and administrative		14,864			14,718			60,837			55,357
Amortization of intangible assets		362			407			1,469			1,606
		28,253			27,754			110,789			102,728
Loss from operations		(5,274	)		(8,171	)		(25,076	)		(29,518	)
Other income (expense):
Investment income (expense), net		1			104			373			(1,404	)
Gain on sale of WorldHeart stock		6,389			—			6,389			313
Other expense, net		102			(235	)		(39	)		(236	)
		6,492			(131	)		6,723			(1,327	)
Loss before provision for income taxes		1,218			(8,302	)		(18,353	)		(30,845	)
Provision for income taxes		243			152			671			752
Net loss	$	975		$	(8,454	)	$	(19,024	)	$	(31,597	)
Basic and diluted net loss per share	$	0.03		$	(0.23	)	$	(0.52	)	$	(0.91	)